Inventor · disambiguated record
Victor Shifrin
Also filed as: SHIFRIN VICTOR
3 granted patents·6 pending applications·5 citations·filing 2003–2024
61Inventor score
Top patents by PatentIndex Score
9 records- 0182US10716837B2Methods and compositions relating to P62 for the treatment and prophylaxis of cancerCURELAB ONCOLOGY INC·Filed 2016·Granted Jul 21, 2020·3 cites·18 claims
- 0269US11098098B2Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseasesCURELAB ONCOLOGY INC·Filed 2018·Granted Aug 24, 2021·1 cites·6 claims
- 0360US9717781B2Methods and compositions relating to P62 for the treatment and prophylaxis of cancerSHNEIDER ALEXANDER·Filed 2012·Granted Aug 1, 2017·1 cites·14 claims
- 0458US2022009985A1Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated DiseasesCURELAB ONCOLOGY INC·Filed 2021·Application pending·0 cites
- 0557US2020338176A1Methods and compositions relating to p62 for the treatment and prophylaxis of cancerCURELAB ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 0656US2025332186A1Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated DiseasesCURELAB ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 0747US2016324944A1Methods and compositions relating to p62/SQSTM1 for the treatment and prevention of inflammation-associated diseasesVENANZI FRANCO·Filed 2014·Application pending·0 cites
- 0841US2005260221A1Hepatitis C virus constructs characterized by high efficiency replicationANADYS PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 0936US2004005549A1Hepatitis C virus constructs characterized by high efficiency replicationANADYS PHARMACEUTICALS INC·Filed 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Victor Shifrin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →